レ点腫瘍学ノート

Top / 支持療法 / 制吐療法

update2017

HECへのオランザピン(ジプレキサ)

ステロイド+5HT3拮抗剤+アプレピタントへのオランザピン10mg上乗せで制吐効果が増加する/NEJM

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting - PubMed
Olanzapine, as compared with placebo, significantly improved nausea prevention, as well as the complete-response rate, among previously untreated patients who were receiving highly emetogenic chemotherapy. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT02116530.).
https://www.ncbi.nlm.nih.gov/pubmed/27410922

日本人でのデータ。ステロイド+5HT3拮抗剤(パロノセトロン)+アプレピタントへのオランザピン5mg上乗せで制吐効果が増加する/Int J Clin Oncol

A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy - PubMed
UMIN000014214.
https://www.ncbi.nlm.nih.gov/pubmed/29039073

HECへのサリドマイド

HECによる遅発性嘔吐をサリドマイドがよく抑制するという話。パロノセトロンとステロイドに制吐剤としてのサリドマイドの併用で完全制御率が15%ほどアップ。ただし避妊に注意(強い縛りあり)。/JCO

Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study) - PubMed
Purpose We examined the efficacy and safety of thalidomide (THD) for the prevention of delayed nausea and vomiting in patients who received highly emetogenic chemotherapy (HEC). Patients and Methods In a randomized, double-blind, active-controlled, phase III trial, chemotherapy-naive patients with c …
https://www.ncbi.nlm.nih.gov/pubmed/28854065

この記事に対するコメント

このページには、まだコメントはありません。

お名前:

更新日:2019-12-16 閲覧数:997 views.